The prevention of prostate cancer - The dilemma continues

New England Journal of Medicine

Volumn 349, Issue 3, 2003, Pages 297-299

  Scardino, Peter T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; STEROID 5ALPHA REDUCTASE;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DISEASE EXACERBATION; EDITORIAL; HUMAN; LABORATORY TEST; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; SEXUAL DYSFUNCTION; SIDE EFFECT; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; MALE; NOTE; PATHOLOGY; PROSTATE TUMOR; RISK ASSESSMENT;

ANTINEOPLASTIC AGENTS, HORMONAL; FINASTERIDE; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0038678851     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe038109     Document Type: Editorial

References (13)

1. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998;338:557-63.
2. Presti JC Jr, Fair WK, Andriole G, et al. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 1992;148:1201-4.
3. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
4. Hoedemaeker R.F, van der Kwast TH, Boer R, et al. Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst 2001;93:1153-8.
5. Smith DS, Humphrey PA, Catalona WJ. The early detection of prostate cancer with prostate specific antigen: the Washington University experience. Cancer 1997;80:1852-6.
6. Scardino PT. The Gordon Wilson Lecture: natural history and treatment of early stage prostate cancer. Trans Am Clin Climatol Assoc 2000;111:201-41.
7. Surveillance, Epidemiology, and End Results (SEER) program. SEER*Stat database: incidence - SEER 9 regs, Nov. 2002 sub (1973-2000). Bethesda, Md.: National Cancer Institute, Cancer Statistics Branch, 2003. (Accessed June 27, 2003, at http://www.seer.cancer.gov.)
8. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-80.
9. Yang XJ, Lecksell K, Short K, et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? Urology 1999;53:696-700.
10. Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Urology 1998;52:195-201.
11. Morgentaler A, Bruning CO III, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996;276:1904-6.
12. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992;267:2215-20.
13. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.